---
schema_version: "secwatch.filing_event.v1"
accession: "0001638833-26-000006"
form_type: "8-K"
ticker: "SGRY"
cik: "0001638833"
company_name: "Surgery Partners, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:40:30.310936+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Surgery Partners Q4 rev $885M (+2.4%), Adj. EBITDA $156.9M (-4.2%), net loss $15M, 2026 guidance, $200M buyback

## Summary
- Revenue $885.0M (+2.4% YoY); full-year $3.3B (+6.2%). Same-facility revenue +3.5% Q4.
- Adj. EBITDA $156.9M (-4.2% YoY); full-year $526.2M (+3.5%). Net loss $15.0M Q4, $77.9M FY.
- 2026 guidance: Adj. EBITDA at least $530M; revenue range $3.35B-$3.45B.
- Board authorized $200M share repurchase program on February 26, 2026.
- Operating cash flow $103.4M Q4 (down from $111.4M); net debt/EBITDA ~4.3x.

## SEC filing metadata
- accession: 0001638833-26-000006
- form_type: 8-K
- ticker: SGRY
- cik: 0001638833
- company_name: Surgery Partners, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638833/000163883326000006/0001638833-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638833/000163883326000006/sgry-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001638833-26-000006
- JSON: https://secwatch.observer/filing/0001638833-26-000006.json
- Plain text: https://secwatch.observer/filing/0001638833-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.